Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- OM:QLINEA
Q-linea Full Year 2023 Earnings: Misses Expectations
Q-linea (STO:QLINEA) Full Year 2023 Results
Key Financial Results
- Net loss: kr229.4m (loss narrowed by 15% from FY 2022).
- kr3.48 loss per share (improved from kr9.20 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Q-linea Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 72%. Earnings per share (EPS) also missed analyst estimates by 53%.
Looking ahead, revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 1.9% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Q-linea (at least 3 which are a bit concerning), and understanding them should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether Q-linea is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Simply Wall St
About OM:QLINEA
Q-linea
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
Adequate balance sheet and slightly overvalued.